Francisco Torrens | Pharmacology | Breakthrough Research Award

Published on by Research Awards

Breakthrough Research Award

             Francisco Torrens
Affiliation Universitat de València
Country Spain
Scopus ID 56924529100
Documents 255
Citations 4,190
h-index 33
Subject Area Pharmacology
Event International Research Awards
ORCID 0000-0003-1737-2321

Francisco Torrens

Universitat de València, Spain

Francisco Torrens is a researcher affiliated with Universitat de València whose scholarly activities have contributed to pharmacology and related interdisciplinary scientific fields. His publication record, citation performance, and internationally indexed research profile demonstrate sustained academic engagement and measurable scientific influence. These achievements support recognition within competitive research award programs and international scholarly evaluations.[1]

Abstract

Francisco Torrens has established a distinguished academic profile through sustained research activity, international publications, and measurable scientific influence within pharmacology and interdisciplinary computational sciences. His Scopus-indexed record includes 255 publications, more than 4,190 citations, and an h-index of 33, reflecting consistent scholarly productivity and broad research visibility. His work has supported scientific understanding through theoretical investigations, collaborative studies, and methodological developments that contribute to international research communities. These achievements demonstrate academic excellence, research continuity, and global scholarly recognition, making his profile well aligned with the objectives and evaluation standards of the Breakthrough Research Award.[1][2]

Keywords

Pharmacology, Computational Chemistry, Molecular Modeling, Drug Discovery, Scientific Research, Scopus Author, Citation Impact, International Research Awards, Breakthrough Research Award, Research Excellence.

Introduction

Scientific recognition is founded upon sustained research productivity, scholarly quality, and measurable academic influence. Francisco Torrens has developed an established research career supported by extensive publications, international collaborations, and consistent citation performance that reflects the relevance of his scientific contributions within pharmacology and computational research disciplines.[1]

Research Profile

Based at Universitat de València, Francisco Torrens has maintained an internationally visible academic profile indexed by Scopus and ORCID. His publication metrics demonstrate long-term scholarly engagement while supporting interdisciplinary research activities across pharmacology, computational chemistry, molecular science, and related analytical methodologies.[1]

Research Contributions

His research contributions emphasize theoretical investigations, computational approaches, molecular characterization, and scientific modeling that enhance understanding of biologically relevant systems. Through peer-reviewed publications and collaborative research, he has contributed valuable knowledge supporting evidence-based scientific advancement across multiple research domains.[2]

Publications

Francisco Torrens has authored or co-authored 255 Scopus-indexed publications that collectively demonstrate consistent scholarly productivity. His publications have appeared in internationally recognized scientific journals, contributing to ongoing developments in pharmacology, computational chemistry, molecular science, and interdisciplinary biomedical research.[1]

Research Impact

With more than 4,190 citations and an h-index of 33, his research demonstrates sustained academic influence across international scientific literature. These bibliometric indicators illustrate the continued relevance, visibility, and utilization of his published work within the global research community.[3]

Award Suitability

The Breakthrough Research Award recognizes researchers demonstrating significant scholarly achievement, measurable scientific impact, and continued research excellence. Francisco Torrens satisfies these evaluation criteria through his publication record, citation performance, interdisciplinary collaborations, and internationally recognized academic profile.[4]

Conclusion

Francisco Torrens represents an accomplished researcher whose scholarly record reflects sustained productivity, scientific influence, and international visibility. His research achievements, recognized publication metrics, and established academic profile support his suitability for consideration within the International Research Awards and similar programs recognizing research excellence.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Francisco Torrens. Author ID 56924529100. Scopus.
    https://www.scopus.com/pages/authors/56924529100
  2. ORCID. (n.d.). ORCID author details: Francisco Torrens.
    https://orcid.org/0000-0003-1737-2321
  3. International Research Awards. (n.d.). Breakthrough Research Award.
    https://researchawards.net/
  4. Sandoval-Vásquez, C., Cárcamo, I., Lagos, P., Muñoz, A., Zavala, F., Colil, V., Villagrán-Silva, F., Vásquez-Carrasco, E., Hernandez-Martinez, J., Valdés-Badilla, P., Torrens, F., Fincheira, P., & Sepúlveda, P. (2025). Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: A systematic review. Frontiers in Pharmacology, 16, 1710176.
    https://doi.org/10.3389/fphar.2025.1710176
  5. Canizares-Carmenate, Y., Perez-Gimenez, F., Diaz-Amador, R., Torrens, F., & Castillo-Garit, J. A. (2025). Discovery of diphenylsilane compounds as potential inhibitors of Zn-metalloproteinase thermolysin using artificial neural networks. Current Computer-Aided Drug Design. Advance online publication.
    https://doi.org/10.2174/0115680266369656250428053942

Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Research Awards

Prof. Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award 

The Second Affiliated Hospital of Nanchang University | China

Dr. Hou-Qun Ying, PhD, born on July 18, 1985, in Shangrao, Jiangxi Province, China, is an accomplished clinical scientist specializing in cancer biomarkers, inflammation-related indices, molecular epidemiology, and therapeutic response prediction. He currently serves as the Vice Director of the Department of Clinical Laboratory Medicine at The Second Affiliated Hospital of Nanchang University, where he plays a leading role in translational research, diagnostic innovation, and clinical laboratory management. Dr. Ying earned his Ph.D. in Clinical Laboratory Diagnosis from Southeast University (2013–2016), after completing his Master of Medicine in Pathogenic Biology at Dali University and his Bachelor of Medicine in Medical Laboratory Science from Tianjin Medical University. His academic and professional journey reflects strong expertise in cancer diagnostics, genetic polymorphisms, biomarker development, and precision medicine. Dr. Ying has successfully led multiple competitive research grants, including the National Natural Science Foundation of China Youth Fund (2018–2020), exploring Hippo-pathway-related genetic variations and EGFR-TKI resistance in non-small cell lung cancer, and the 2024–2027 Regional Fund focusing on SP1 transcription factor–related genetic variations as biomarkers for bevacizumab resistance in metastatic colorectal cancer. His research contributions span more than 70 peer-reviewed publications, with many as first, co-first, or corresponding author in high-impact journals such as Scientific Reports, Oncotarget, Cancer Medicine, Therapeutic Advances in Medical Oncology, Frontiers in Oncology, Pharmacological Research, Biomarkers, Future Oncology, and J Inflammation Research. His studies have provided pivotal insights into inflammatory markers such as fibrinogen-to-pre-albumin ratio, albumin-to-fibrinogen ratio, dNLR, PLR, and novel composite biomarkers for cancer prognosis, treatment response prediction, early diagnosis, and recurrence risk stratification. He has also made influential contributions to colorectal cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma, and NSCLC through biomarker innovation, clinical prediction models, and meta-analytic evaluations. As a corresponding author, Dr. Ying has developed and validated numerous inflammation-based and genetic biomarker signatures, such as FPR, ADS score, MLPAS, CCMLP, and chronic inflammation indices, improving precision therapeutic decisions for chemotherapy, bevacizumab, 5-FU–based regimens, and TKIs. Additionally, his collaborative work extends to machine learning applications in early gastric cancer prediction, molecular mechanisms underlying cancer progression, and multi-omics approaches. With a distinguished record of scientific leadership, grant success, and impactful publications, Dr. Ying continues to advance clinical oncology diagnostics and personalized treatment strategies through rigorous research, innovation, and interdisciplinary collaboration.

Profiles: Scopus | Orcid

Featured Publications

Peng, Y., Shang, R., Wang, Z.-J., Ye, Q.-Y., Tang, X.-Y., Cheng, X.-X., & Ying, H.-Q. (2025). Chronic inflammatory comprehensive signature predicts oxaliplatin and 5-fluorouracil benefit in early colorectal cancer. Drug Design, Development and Therapy. https://doi.org/10.2147/DDDT.S556619

Lu, Y., Ye, Q.-Y., Mei, O., Li, Y.-N., Peng, Y., Ying, H.-Q., & Cheng, X.-X. (2025). Chronic inflammation index-based tumor subsite classification correlated with chemotherapy benefit and survival outcomes in stage II–III colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S517378

Ye, Q.-Y., Wang, Y.-Y., Wang, Z.-J., Lu, M., Peng, H.-X., Wang, X., Cheng, X.-X., & Ying, H.-Q. (2025). Robust predictive performance of MLPAS and CCMLP for clinical outcome and risk stratification in patients with colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S498028

Tian, H., Liu, Z., Zhang, Z., Zhang, L., Zong, Z., Liu, J., Ying, H., & Li, H. (2023). Clinical significance of fibrinogen and platelet to pre-albumin ratio in predicting the prognosis of advanced gastric cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S412033

Ying, H.-Q., Liao, Y.-C., Luo, Y.-R., Xiong, G., Huang, Y., Nie, R.-W., Xiong, C.-F., & Cheng, X.-X. (2021). Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naïve patients with advanced NSCLC. Pharmacological Research, 105734. https://doi.org/10.1016/j.phrs.2021.105734

Ying, H.-Q., You, X.-H., Liao, Y.-C., Sun, F., & Cheng, X.-X. (2021). High-grade inflammation attenuates chemosensitivity and confers poor survival of surgical stage III CRC patients. Frontiers in Oncology, 11, 580455. https://doi.org/10.3389/fonc.2021.580455

Liao, Y.-C., Ying, H.-Q., Huang, Y., Luo, Y.-R., Xiong, C.-F., Nie, R.-W., Li, X.-J., & Cheng, X.-X. (2021). Role of chronic inflammatory ratios in predicting recurrence of resected patients with stage I–III mucinous colorectal adenocarcinoma. Cancer Management and Research, 13, 303758. https://doi.org/10.2147/CMAR.S303758

Mekkanti Manasa Rekha | Pharmaceutical Science | Young Scientist Award | 13652

Published on by Research Awards

Dr. Mekkanti Manasa Rekha | Pharmaceutical Science | Young Scientist Award |

Aditya Bangalore Institute of Pharmacy Education and Research | India

Dr. Mekkanti Manasa Rekha, Pharm.D, RPh, (Ph.D.), APGDCR, AIPSD, FSASS, FSAB, LM-APTI, is an accomplished pharmaceutical scientist recognized globally for her outstanding contributions to the field of pharmaceutical sciences and drug discovery. A Gold Medalist and University Topper from the 2011–2017 Pharm.D batch at Annamacharya College of Pharmacy, Dr. Rekha has demonstrated exceptional academic and research excellence throughout her career. She has actively participated in over 120 National and International conferences, UGC-sponsored workshops, webinars, and academic competitions, earning 102 awards across diverse platforms including science fairs, talent search exams, essay and quiz competitions. Her prolific research output includes over 200 publications in reputed national and international journals with good impact factors, contributing significantly to the scientific community. She has been granted 25 patents and has authored 20 books/book chapters, focusing on cutting-edge areas of pharmaceutical research. Dr. Rekha has achieved an impressive citation count exceeding 434, with an h-index of 9, reflecting the influence and quality of her scholarly work (Note: Insert exact numbers as available). She has received 12 Best Speaker Awards at various global scientific congresses. A dedicated researcher and academician, she has guided numerous Pharm.D, B.Pharm, and M.Pharm research projects, and worked on over 78 major research projects. She currently serves as an Editor, Associate Editor, Peer Reviewer, and Chief Advisory Board Member for 52 reputed national and international journals. Additionally, she has held critical roles such as Chief Biological Scientist in Animal Ethics Committees and Chief Member of Human Ethics Committees. Her career is a testament to her unwavering passion for research, innovation, and academic excellence in the pharmaceutical sciences.

Profiles: Google Scholar | Staff Page

Featured Publications

Bradha, M., Balakrishnan, N., Suvitha, A., Arumanayagam, T., Rekha, M., & Others. (2022). Experimental, computational analysis of Butein and Lanceoletin for natural dye-sensitized solar cells and stabilizing efficiency by IoT. Environment, Development and Sustainability, 24(6), 8807–8822.

Kumar, B. A., Rekha, M. M., & Mubeena, T. (2016). A short review on Zika Virus past, present strategies and future prospectives. PharmaTutor, 4(7), 21–24.

Sead, F. F., Jain, V., Kumar, A., Rekha, R. M. M., Kundlas, M., Gupta, S., Kumari, M., & Others. (2025). Magnetically recoverable catalysts for efficient multicomponent synthesis of organosulfur compounds. RSC Advances, 15(5), 3928–3953.

Vivek, P., Kumar, G. S., Steephen, A., Jauhar, R. O. M. U., Suvitha, A., Rekha, M., & Others. (2021). Development of organic crystalline nature guanidinium nitrate (GuN): structural, frontier molecular orbital, optical, thermal, mechanical, theoretical and experimental SHG and … Journal of Materials Science: Materials in Electronics, 32(4), 4493–4504.

Vivek, P., Rekha, M., Steephen, A., Kowsalya, M., & Magesh, M. (2021). Meticulous review on potential nano-sized catalysts for air and water purifiers. Iranian Journal of Catalysis, 11(4).

Balaraman, A. K., Babu, M. A., Moglad, E., Mandaliya, V., Rekha, M. M., Gupta, S., & Others. (2025). Exosome-mediated delivery of CRISPR-Cas9: A revolutionary approach to cancer gene editing. Pathology – Research and Practice, 266, 155785.

Rekha, K., Aruna, R. M., Rekha, M. M., & Karthik, S. (2019). Formulation and development of bilastine tablets 20 mg. World Journal of Pharmaceutical Research, 8, 2197–224.

Wankhede, N. L., Kale, M. B., Kyada, A., Rekha, R. M. M., Chaudhary, K., Naidu, K. S., & Others. (2025). Sleep deprivation-induced shifts in gut microbiota: Implications for neurological disorders. Neuroscience, 565, 99–116.

Vivek, P., Rekha, M., Steephen, A., Jauhar, R. O. M., Kumar, G. S., Suvitha, A., & Others. (2021). Nonlinear optical crystalline nature bis(2,6-diaminopyridinium) hydrogen phthalate nitrate monohydrate (APPN): Development and its phase matching nature. Results in Optics, 3, 100075.